The Sino-EU PerMed project, launched in January 2020, is a bi-regional consortium of six partners from governmental, funding and research organisations to promote personalised medicine cooperation between Europe and China.
The project was set up as part of a concerted larger effort by the European Commission to increase international collaboration to promote personalised medicine and was devised to engage China in the International Consortium on Personalised Medicine [ICPerMed] – an EU Member States driven initiative and advance the implementation of the Strategic Research and Innovation Agenda on personalised medicine.
This Euractiv report explains the purpose of the project, what it set out to achieve, and the expected outcomes.
-
As China-EU personalised medicines partnership comes to an end, what comes next?
Est. 4minAs tensions between the European Union and China continue to simmer, could a Sino-EU personalised medicine project bridge gaps and foster bilateral cooperation?
-
Sino-EU personalised medicine project, Europe bridging a data divide
Est. 8minThe Sino-EU PerMed project was created in 2020 to foster cooperation between Europe and China in personalised medicine. As the project prepares to wrap up, Euractiv spoke with Toscana Life Sciences' Gianni D'Errico, to discuss lessons learned and the road ahead.
-
Europe-China cooperation in personalised medicine: paving the way for a scientific common path
Est. 4minWithin the Sino-Eu PerMed Project three delegation visits were organised to foster and increase cooperation between China and Europe. As a result of these visits a policy brief on ethical legal and societal aspects in personalised medicine has been published.